Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Epinephrine

The articles shown below are all about the Epinephrine, through these related articles, you can get relevant information, notes in use, or latest trends about the Epinephrine. We hope these news will give you the help you need. And if these Epinephrine articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 08 2025

    2025-09-08

    This week, there are 6 drugs in the patent and exclusivity list. They are: - GERON CORP's RYTELO, containing active ingredient IMETELSTAT SODIUM - MYLAN SPECIALTY LP's EPIPEN JR., containing active ingredient EPINEPHRINE - MYLAN SPECIALTY LP's EPIPEN, containing active ingredient EPINEPHRINE - BAUSCH AND LOMB INC's PROLENSA, containing active ingredient BROMFENAC SODIUM - EISAI INC's HALAVEN, containing active ingredient ERIBULIN MESYLATE - MERIDIAN MEDICAL TECHNOLOGIES LLC's SEIZALAM, containing active ingredient MIDAZOLAM HYDROCHLORIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 28 2025

    2025-04-28

    This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 18 2024

    2024-11-18

    This week, there are 8 drugs in the patent and exclusivity list. They are: - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - BRISTOL MYERS SQUIBB's REVLIMID, containing active ingredient LENALIDOMIDE - CUMBERLAND PHARMACEUTICALS INC's CALDOLOR, containing active ingredient IBUPROFEN - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM - AADI BIOSCIENCE INC's FYARRO, containing active ingredient SIROLIMUS Read More